Skip to main content
. 2020 Feb 22;18:99. doi: 10.1186/s12967-020-02273-4

Fig. 5.

Fig. 5

Correlations between somatic mutation status and patient survival. No significant differences were found in progression free survival (PFS) and overall survival (OS) between patients with a KRAS wild-type tumors and KRAS mutated tumors; b PIK3CA wild-type and PIK3CA mutated tumors; c BRAF wild-type and BRAF mutated tumors